Lantheus Holdings Inc. (NASDAQ:LNTH) traded down 10.8% during mid-day trading on Monday . The stock traded as low as $5.21 and last traded at $5.35, with a volume of 395,725 shares traded. The stock had previously closed at $6.00.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 target price on the stock in a report on Monday. Jefferies Group reiterated a “buy” rating on shares of Lantheus Holdings in a research report on Wednesday, May 4th. Robert W. Baird reiterated a “hold” rating on shares of Lantheus Holdings in a research report on Monday, April 11th. Finally, Credit Suisse Group AG set a $4.00 price target on Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $5.80.

The stock’s 50-day moving average is $4.04 and its 200 day moving average is $2.60. The firm’s market capitalization is $188.16 million.

Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.18. The firm had revenue of $78 million for the quarter, compared to analysts’ expectations of $72.66 million. Equities research analysts forecast that Lantheus Holdings Inc. will post $0.48 EPS for the current fiscal year.

Lantheus Holdings, Inc is a holding company. The Company, through Lantheus Medical Imaging, Inc, develops, manufactures, sells and distributes diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. It operates in two geographical segments: U.S.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.